BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

NCT01894672 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: LGX818

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]